Andrea Necchi, Mathieu Roumiguié, Ashish M Kamat, Neal D Shore, Joost L Boormans, Ahmet Adil Esen, Thierry Lebret, Shuya Kandori, Dean F Bajorin, Laurence E M Krieger, Scot A Niglio, Edward M Uchio, Ho Kyung Seo, Ronald de Wit, Eric A Singer, Petros Grivas, Hiroyuki Nishiyama, Haojie Li, Pranshu Baranwal, Margot Van den Sigtenhorst-Fijlstra, Ekta Kapadia, Girish S Kulkarni
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial
The Lancet. Oncology
longitudinal studies dementia parkinson disease pd reported proportion patients pd eventually develop dementia unknownto examine 8year prevalence characteristics risk factors dementia patients pdpatients recruited epidemiological study pd county rogaland norway using explicit criteria pd subjects cognitive impairment disease onset excluded semistructured caregiverbased interview cognitive rating scales neuropsychological tests used diagnose dementia according criteria diagnostic statistical manual mental disorders revised third edition baseline 4 8 years later populationbased sample 3295 subjects municipality odense denmark used comparison group examined baseline 2 5 yearswe included 224 patients pd 116 women baseline 51 patients 26 dementia fiftyfive patients died 10 refused followup without dementia status known fortythree 28 new cases dementia identified 4 8year evaluations respectively 4year prevalence dementia pd nearly 3 times higher nonpd group 8year prevalence pd 782 95 confidence interval ci 711840 risk factors dementia hallucinations baseline odds ratio 31 95 ci 1662 akineticdominant mixed tremorakinetic pd 33 95 ci 1285more three quarters representative pd cohort developed dementia 8year study period early hallucinations akineticdominant pd associated increased risk dementia